HopeStage
Back to all studies
CompletedNCT03726658

Zelquistinel for Adults With Major Depression

About this titleRead the official source — NCT03726658

Researchers compared AGN-241751 and placebo to find out how the approaches affected depression symptoms in adults with depression.

Medication studyAges 18–65United States
The study in practice

Understand this study

What did researchers investigate?

Researchers compared AGN-241751 and placebo to find out how the approaches affected depression symptoms in adults with depression.

Who was this study for?

This study was for people with depression. Listed age limits: 18 years to 65 years. Other eligibility criteria applied.

Listed locations
Phoenix and 4 more locationsSee all locations and recruitment
Study phase
Phase 1 / Phase 2This study spans more than one phase, so it may combine goals such as safety, dosing, and early effectiveness.

Get this study by email

HopeStage may email me about this study.
Loading the security check...
Study clarity

Study information

Study start dateStarted: November 8, 2018
Recruitment status
Completed
Enrollment listed in the registry
226
Sponsor
Syndeio Biosciences, Inc
Sponsor type
Biotech company
Study type
Drug
Intervention type
Drug
Study phase
Phase 1 / Phase 2This study spans more than one phase, so it may combine goals such as safety, dosing, and early effectiveness.
Locations
United States
Age range
From 18 Years to 65 Years
Official registry ID
NCT03726658
Official title
Show the full official title

A Two-Part, Double-Blind, Placebo-Controlled, Single- and Multiple-Dose (Part A) or Twice Daily Dose (Part B) Study of AGN-241751 in Adult Participants With Major Depressive Disorder

Looking for a study you can join?

Explore recruiting studies

Recruitment & locations

Completed

Phoenix · Garden Grove · Atlanta

2 more locations
  • Berlin
  • Bellevue

Interested in joining this study?

HopeStage may email me about this study.
Loading the security check...
FAQ

Questions about this study

What did researchers investigate?

Researchers compared AGN-241751 and placebo to find out how the approaches affected depression symptoms in adults with depression.

Who is behind this study?

The study sponsor is Syndeio Biosciences, Inc.

Did this study involve medication?

Yes. The study involved medication, including AGN-241751 and Placebo.

Who was this study for?

This study was for people with depression. Listed age limits: 18 years to 65 years. Other eligibility criteria applied.

Want to explore more studies?

Explore studies